首页> 美国卫生研究院文献>Oncotarget >Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

【2h】

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

机译：皮下注射5-阿扎胞苷和恩替司他联合治疗转移性结直肠癌（mCRC）的表观遗传学研究：2期联合体/立位2期癌症研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTherapy with demethylating agent 5-azacitidine and histone deacetylase inhibitor entinostat shows synergistic re-expression of tumor-suppressor genes and growth inhibition in colorectal (CRC) cell lines and in vivo studies.

机译：目的使用脱甲基化剂5-氮杂胞苷和组蛋白脱乙酰基酶抑制剂恩替司他进行的治疗显示出抑癌基因的协同重新表达，并在结直肠（CRC）细胞系和体内研究中表现出生长抑制作用。

著录项

期刊名称 Oncotarget
作者
Nilofer S. Azad; Anthony el-Khoueiry; Jun Yin; Ann L. Oberg; Patrick Flynn; Douglas Adkins; Anup Sharma; Daniel J. Weisenberger; Thomas Brown; Prakriti Medvari; Peter A. Jones; Hariharan Easwaran; Ihab Kamel; Nathan Bahary; George Kim; Joel Picus; Henry C. Pitot; Charles Erlichman; Ross Donehower; Hui Shen; Peter W. Laird; Richard Piekarz; Stephen Baylin; Nita Ahuja;
展开▼
作者单位

展开▼
年(卷),期 2017(8),21
年度 2017
页码 35326–35338
总页数 13
原文格式 PDF
正文语种
中图分类肿瘤学 ; 细胞生物学 ;
关键词
epigenetics colorectal cancer DNA methyltransferases inhibitors histone deacetylase inhibitors;

机译：表观遗传学;结肠直肠癌;DNA甲基转移酶抑制剂;组蛋白脱乙酰基酶抑制剂;

相似文献

外文文献
中文文献
专利

1. 3061 POSTER Phase I/II study of novel oral fluoropyrimidine S-1 in combination with oxaliplatin (SOX) as first-line chemotherapy for metastatic colorectal cancer (mCRC) [J] . M.Tahara, Y.Yamada, A.Ohtsu, European Journal of Cancer Supplements . 2007 ,第4期

机译：新型口服氟嘧啶S-1联合奥沙利铂（SOX）作为转移性结直肠癌（mCRC）一线化疗的3061 POSTER I / II期研究
2. 465 POSTER Phase I/II study of oxaliplatin (L-OHP) in combination with S-1 (SOX) as first-line therapy for metastatic colorectal cancer (MCRC) [J] . Y.Yamada, A.Ohtsu, M.Tahara, European Journal of Cancer Supplements . 2006 ,第12期

机译：奥沙利铂（L-OHP）联合S-1（SOX）作为转移性结直肠癌（MCRC）一线治疗的465 POSTER I / II期研究
3. 329?Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab [J] . Tom Lillie, Andrew Stone, Sarah Lockwood, Journal for ImmunoTherapy of Cancer . 2020 ,第Suppla3期

机译：329？在香料中延长了转移性结肠直肠癌（MCRC）的患者的整体存活（OS），我将enadenotucirev与Nivolumab组合研究
4. PROSPECTIVE TRIAL OF 5-AZACITIDINE IN DOGS WITH NATURALLY-OCCURRING INVASIVE URINARY BLADDER CANCER, AN EPIGENETIC APPROACH TO CANCER THERAPY. [C] . Noah Hahn, Deborah Knapp, Michael Childress, Annual Conference of the Veterinary Cancer Society . 2009

机译：患有自然侵袭性膀胱癌的5-氮杂氨酸的前瞻性试验，癌症治疗的表观遗传方法。
5. New Models of Colorectal Cancer to Facilitate Therapy Development for Metastatic Disease [D] . O'Rourke, Kevin. 2017

机译：新型结肠直肠癌促进转移性疾病治疗的疗效
6. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: a Phase II National Cancer Institute/Stand Up to Cancer Study [O] . Roisin M Connolly, Huili Li, Rachel C Jankowitz, -1

机译：5-阿扎胞苷和恩替司他联合治疗晚期乳腺癌的表观遗传疗法：美国国家癌症研究所II期/癌症研究立项
7. Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC) : results of the AIO KRK 0207 phase III\ua0study [O] . Hegewisch-Becker, Susanna, Arnold, Dirk, Lerchenmufcller, Christian, 2014

机译：标准方法联合使用FP，奥沙利铂（Ox）和Bev作为转移性结直肠癌（mCRC）患者的一线治疗后，采用氟嘧啶（FP）加贝伐单抗（Bev），单独或不进行治疗的维持策略AIO KRK 0207第III阶段\ ua0研究

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

摘要

著录项

相似文献

相关主题

期刊订阅